Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64300535 in Healthy Participants
NCT04736147Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JNJ-64300535 in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants Responding Against Hepatitis B Virus (HBV) Core or Polymerase (Pol) Vaccine Antigens at Day 67. Started Feb 2021; status: completed.
02
Drugs
JNJ-64300535
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04736147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736147.